Singapore, April 22 -- Andelyn Biosciences, ("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific (APAC) regions to accelerate the global delivery of life-changing gene therapies.

The partnership leverages both companies' industry-leading GMP manufacturing facilities, technical expertise, and extensive regional networks to fast-track the development, manufacturing, and global expansion of client programs that deliver next-generation gene therapi...